Compare WYY & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYY | PLYX |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.3M | 112.7M |
| IPO Year | 2005 | 2025 |
| Metric | WYY | PLYX |
|---|---|---|
| Price | $7.77 | $1.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 357.9K | 22.2K |
| Earning Date | 08-13-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.53 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $150,545,364.00 | N/A |
| Revenue This Year | $12.26 | N/A |
| Revenue Next Year | $25.66 | N/A |
| P/E Ratio | $746.23 | ★ N/A |
| Revenue Growth | ★ 5.59 | N/A |
| 52 Week Low | $3.96 | $1.85 |
| 52 Week High | $24.30 | $9.18 |
| Indicator | WYY | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 46.50 |
| Support Level | $4.46 | $2.03 |
| Resistance Level | $12.69 | $2.21 |
| Average True Range (ATR) | 1.23 | 0.10 |
| MACD | -0.46 | 0.00 |
| Stochastic Oscillator | 40.88 | 34.89 |
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.